Le Lézard
Classified in: Health
Subject: SVY

Patient Safety Solutions to Prevent up to 70% of Adverse Events


SANTA CLARA, Calif., Feb. 22, 2018 /CNW/ -- Frost & Sullivan's recent analysis, Patient Safety in Healthcare, Forecast to 2022, assesses the 30 most pressing safety adverse events affecting patients, caregivers, and healthcare organizations across the globe. Cumulatively, these adverse episodes affected an estimated 91.8 million patient admissions across the US and Western Europe resulting in around 1.95 million deaths at an average mortality of 2.1 percent and a significantly higher morbidity. The study also covers innovative and promising solutions, future market potential, convergence of new technologies, key market participants, competitive landscape, and investment trends.

In the next four years, adverse patient safety events in the United States and Western Europe such as healthcare associated infections (HAIs), sepsis, medication safety, pressure ulcers, diagnostic errors, antibiotic resistance and hand hygiene non-compliance will drive an estimated healthcare cost burden of $383.7 billion. While some adverse events, such as medication safety and hand hygiene non-compliance, are relatively well addressed by current industry solutions, under-penetrated areas such as antibiotic resistance, pressure ulcers, sepsis and unnecessary ED (emergency department) admissions will be the high opportunity growth areas for future.

For further information on this analysis, please visit: http://frost.ly/262.

Further trends driving growth in the patient safety market include:

"Up to 17 percent of all hospitalizations are affected by one or more adverse events and around 15% of hospital expenditure is attributable to addressing them. The fact that 30 to 70 percent of these are potentially avoidable makes it imperative to prevent them from happening," said Anuj Agarwal, Transformational Healthcare Senior Research Analyst at Frost & Sullivan. "To reap growth opportunities, care providers and market participants should target their patient safety value proposition toward low-penetration areas with significant disruptive potential like antibiotic resistance, cybersecurity, avoidable ED admissions, pressure ulcers, and sepsis."

In the next four years, Frost & Sullivan predicts the following developments:

"The lack of clarity on available business models, fragmented and isolated vendor solutions addressing a specific set of issues in a particular segment, and disagreement on ideal patient safety solutions and implementation costs are major hurdles currently facing the market," observed Agarwal.

Patient Safety in Healthcare, Forecast to 2022 is part of Frost & Sullivan's Transformational Health Growth Partnership Service program.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.

Patient Safety in Healthcare, Forecast to 2022
K200_54

Contact:
Mariana Fernandez
Corporate Communications ? North America
P: +1 (210) 348 1012
E: [email protected]

http://ww2.frost.com
twitter: @FS_Healthcare  
LinkedIn: Transform Health

 

SOURCE Frost & Sullivan


These press releases may also interest you

at 16:35
Geron Corporation , a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results and business highlights before the market opens on Thursday, May 2, 2024 via press release, which will...

at 16:35
Tilray Brands, Inc. , a leader in the craft beer and cannabis-lifestyle industries, celebrates high honors and awards at the 2024 Craft Brewer's Conference and World Beer Cup. 10 Barrel Brewing won four craft beer awards and 10...

at 16:34
Fusion Pharmaceuticals Inc. , a clinical-stage oncology company focused on developing next-generation radioconjucates (RCs) as precision medicines, today announced that it has filed and is in the process of mailing the management information circular...

at 16:30
In an important step toward driving long-term affordability and access to treatments for chronic and complex conditions, Evernorth Health Services announced that it will have a Humira® biosimilar available for $0 out of pocket for eligible...

at 16:28
Dr. Siva Mohan, Co-Founder and Chief Medical Officer of RazorMetrics, an Austin-based drug cost reduction platform, is the Best Entrepreneur - Health Products & Services Status: Silver Stevie Winner from the American Business Awards. The Stevie®...

at 16:20
The Board of Directors of Revvity , today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 9, 2024 to all shareholders of record at the close of business on July 19, 2024. About Revvity ...



News published on and distributed by: